Proteomic Profiling in Predicting Response in Patients Receiving Erlotinib for Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- David Carbone, M.D., Ph.D.
Vanderbilt-Ingram Cancer Center
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
7 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- University of Florida Shands Cancer Center
Gainesville, Florida, United States
- Emory University
Atlanta, Georgia, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center - Cool Springs
Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center at Franklin
Nashville, Tennessee, United States
- M. D. Anderson Cancer Center at University of Texas
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Oct 2007
- Primary completion
- 30 Sept 2011
- Completion
- 31 Dec 2013
- Last update posted
- 8 Jun 2017
- Registered enrollment
- 116
- Registry id
- NCT00550537
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.